GlobeNewswire

GALECTIN THERAPEUTICS ANNOUNCES POSITIVE NEW PSORIASIS AND ATOPIC DERMATITIS CLINICAL DATA, SEEKING STRATEGIC PARTNERSHIPS FOR THERAPY OF SEVERE SKIN DISEASES

GALECTIN THERAPEUTICS ANNOUNCES POSITIVE NEW PSORIASIS AND ATOPIC DERMATITIS CLINICAL DATA, SEEKING STRATEGIC PARTNERSHIPS FOR THERAPY OF SEVERE SKIN DISEASES

Patient who showed marked clinical improvement in his psoriasis (72 percent improvement in PASI) after treatment with the galectin-3 inhibitor GR-MD-02
Format

JPEG

Source

Galectin Therapeutics Inc.

Downloads